RGD Reference Report - Lipoprotein abnormalities in patients with atherosclerotic renovascular disease. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Lipoprotein abnormalities in patients with atherosclerotic renovascular disease.

Authors: Nowakowska Fortuna, E  Herlitz, H  Saeed, A  Attman, PO  Jensen, G  Alaupovic, P  Guron, G 
Citation: Nowakowska Fortuna E, etal., Kidney Blood Press Res. 2011;34(5):311-9. doi: 10.1159/000325648. Epub 2011 May 26.
RGD ID: 7207208
Pubmed: PMID:21613792   (View Abstract at PubMed)
DOI: DOI:10.1159/000325648   (Journal Full-text)

BACKGROUND: Patients with atherosclerotic renovascular disease (ARVD) have a high risk of cardiovascular death. The primary aim was to characterize abnormalities in apolipoprotein (Apo)-defined lipoprotein (Lp) subclasses in patients with ARVD. METHODS: Baseline measurements were performed on 42 patients with ARVD 4 weeks after renal angioplasty (PTRA). All patients were on statin treatment. Twenty age-matched healthy subjects without medications served as controls. Subsequently, patients were randomized to treatment with either candesartan (n = 21), or antihypertensive treatment without inhibitors of the renin-angiotensin-aldosterone system (n = 21) and followed for 11 months. RESULTS: At baseline, ApoC-III (12.7 +/- 4.6 vs. 8.8 +/- 2.6 (SD) mg/dl, p < 0.05), LpB:C:E (13.3 +/- 5.4 vs. 8.4 +/- 4.3 mg/dl, p < 0.05), and the sum of ApoC-III-containing lipoproteins, i.e. LpB:C + LpB:C:E + LpA-II:B:C:D:E (46 +/- 15 vs. 37 +/- 8 mg/dl, p < 0.05), were significantly elevated in ARVD patients versus healthy controls. Multiple regression analyses showed that only plasma renin activity was independently associated with ApoC-III levels at baseline (p < 0.05, r = 0.74). Treatment with candesartan did not correct abnormalities. CONCLUSIONS: Patients with ARVD treated with statins have an atherogenic lipoprotein profile characterized by elevated levels of ApoC-III-containing, triglyceride-rich lipoproteins that could accelerate atherosclerotic disease.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
APOC3Humanrenal artery obstruction  IEP protein:increased expression:plasmaRGD 
Apoc3Ratrenal artery obstruction  ISOAPOC3 (Homo sapiens)protein:increased expression:plasmaRGD 
Apoc3Mouserenal artery obstruction  ISOAPOC3 (Homo sapiens)protein:increased expression:plasmaRGD 

Objects Annotated

Genes (Rattus norvegicus)
Apoc3  (apolipoprotein C3)

Genes (Mus musculus)
Apoc3  (apolipoprotein C-III)

Genes (Homo sapiens)
APOC3  (apolipoprotein C3)


Additional Information